Peeling Back The Layers: Exploring Xencor Through Analyst Insights
In the latest quarter, 5 analysts provided ratings for Xencor (NASDAQ:XNCR), showcasing a mix of bullish and bearish…
Decoding 6 Analyst Evaluations For Xencor
6 analysts have shared their evaluations of Xencor (NASDAQ:XNCR) during the recent three months, expressing a mix of…
Analyst Scoreboard: 6 Ratings For Xencor
In the preceding three months, 6 analysts have released ratings for Xencor (NASDAQ:XNCR), presenting a wide array of…
Navigating 4 Analyst Ratings For Xencor
Across the recent three months, 4 analysts have shared their insights on Xencor (NASDAQ:XNCR), expressing a variety of…
Xencor Sells Portion Of Royalties And Milestones From Ultomiris And Monjuvi To OMERS Life Sciences For $215M
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the sale of portions of financial
Recap: Xencor Q3 Earnings
Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Tuesday, November 7, 2023 at 04:01 PM. Here’s what investors…
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell
• CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Preview: Xencor’s Earnings
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Tuesday, 2023-11-07. Here’s what investors need…
Xencor Presents Preclinical Data From Multiple XmAb Research Programs At The SITC Annual Meeting
Clinical Trials in ProgressAbstract 764, "A Phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with
